2017 Q1 Form 10-K Financial Statement
#000156459017003722 Filed on March 08, 2017
Income Statement
Concept | 2017 Q1 | 2016 Q4 | 2015 Q4 |
---|---|---|---|
Revenue | $270.0K | $70.00K | $110.0K |
YoY Change | 145.45% | -36.36% | -13.39% |
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $2.380M | $2.180M | $3.030M |
YoY Change | -0.83% | -28.05% | 180.56% |
% of Gross Profit | |||
Research & Development | $2.061M | $3.110M | $1.770M |
YoY Change | -9.84% | 75.71% | 26.43% |
% of Gross Profit | |||
Depreciation & Amortization | $48.00K | $100.0K | $100.0K |
YoY Change | -54.29% | 0.0% | -75.0% |
% of Gross Profit | |||
Operating Expenses | $4.442M | $5.290M | $4.794M |
YoY Change | -5.11% | 10.35% | 94.09% |
Operating Profit | -$4.171M | -$4.683M | |
YoY Change | -8.77% | 160.46% | |
Interest Expense | $17.00K | $40.00K | -$450.0K |
YoY Change | -98.27% | -108.89% | -190.0% |
% of Operating Profit | |||
Other Income/Expense, Net | $16.00K | ||
YoY Change | -20.0% | ||
Pretax Income | -$4.140M | -$3.750M | -$5.130M |
YoY Change | 15.32% | -26.9% | 294.62% |
Income Tax | |||
% Of Pretax Income | |||
Net Earnings | -$4.138M | -$3.750M | -$5.129M |
YoY Change | 15.2% | -26.89% | 293.93% |
Net Earnings / Revenue | -1532.59% | -5357.14% | -4662.73% |
Basic Earnings Per Share | |||
Diluted Earnings Per Share | -$4.549M | -$4.688M | -$6.662M |
COMMON SHARES | |||
Basic Shares Outstanding | 1.000M | 12.03M | 11.43M shares |
Diluted Shares Outstanding |
Balance Sheet
Concept | 2017 Q1 | 2016 Q4 | 2015 Q4 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $14.50M | $17.10M | $32.50M |
YoY Change | -47.65% | -47.38% | 2066.67% |
Cash & Equivalents | $14.53M | $10.26M | $29.10M |
Short-Term Investments | $0.00 | $6.800M | $3.400M |
Other Short-Term Assets | $13.70M | $20.50M | $35.70M |
YoY Change | -58.1% | -42.58% | 8825.0% |
Inventory | |||
Prepaid Expenses | |||
Receivables | $200.0K | $0.00 | $500.0K |
Other Receivables | $0.00 | $0.00 | $0.00 |
Total Short-Term Assets | $28.54M | $37.52M | $68.70M |
YoY Change | -53.02% | -45.38% | 3218.74% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $399.0K | $444.0K | $698.0K |
YoY Change | -41.5% | -36.39% | -23.38% |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $100.0K | $100.0K | $100.0K |
YoY Change | 0.0% | 0.0% | 733.33% |
Total Long-Term Assets | $524.0K | $569.0K | $823.0K |
YoY Change | -35.07% | -30.86% | -9.66% |
TOTAL ASSETS | |||
Total Short-Term Assets | $28.54M | $37.52M | $68.70M |
Total Long-Term Assets | $524.0K | $569.0K | $823.0K |
Total Assets | $29.06M | $38.09M | $69.52M |
YoY Change | -52.78% | -45.21% | 2232.14% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $899.0K | $837.0K | $939.0K |
YoY Change | 25.38% | -10.86% | 277.11% |
Accrued Expenses | $1.400M | $1.400M | $1.500M |
YoY Change | 40.0% | -6.67% | -40.22% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $12.70M | $19.40M | $33.70M |
YoY Change | -58.9% | -42.43% | |
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $15.22M | $21.97M | $37.76M |
YoY Change | -54.32% | -41.82% | 1516.27% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | $0.00 | $100.0K | $300.0K |
YoY Change | -100.0% | -66.67% | -72.73% |
Total Long-Term Liabilities | $0.00 | $100.0K | $300.0K |
YoY Change | -100.0% | -66.67% | -72.73% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $15.22M | $21.97M | $37.76M |
Total Long-Term Liabilities | $0.00 | $100.0K | $300.0K |
Total Liabilities | $15.22M | $22.02M | $38.10M |
YoY Change | -54.63% | -42.2% | 1002.31% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$152.1M | -$148.0M | -$131.0M |
YoY Change | 12.99% | 12.93% | 12.7% |
Common Stock | $2.000K | $1.000K | $1.000K |
YoY Change | -81.82% | 0.0% | -97.06% |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $13.84M | $16.07M | $31.43M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $29.06M | $38.09M | $69.52M |
YoY Change | -52.78% | -45.21% | 2232.14% |
Cashflow Statement
Concept | 2017 Q1 | 2016 Q4 | 2015 Q4 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$4.138M | -$3.750M | -$5.129M |
YoY Change | 15.2% | -26.89% | 293.93% |
Depreciation, Depletion And Amortization | $48.00K | $100.0K | $100.0K |
YoY Change | -54.29% | 0.0% | -75.0% |
Cash From Operating Activities | -$4.300M | -$5.000M | -$5.100M |
YoY Change | -8.51% | -1.96% | -120.4% |
INVESTING ACTIVITIES | |||
Capital Expenditures | $3.000K | -$200.0K | -$100.0K |
YoY Change | -96.63% | 100.0% | |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $6.800M | $6.000M | $11.00M |
YoY Change | -283.78% | -45.45% | -156.41% |
Cash From Investing Activities | $6.800M | $5.800M | $11.00M |
YoY Change | -278.95% | -47.27% | -156.41% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | $1.782M | ||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | -5.000M | 0.000 | 200.0K |
YoY Change | -100.0% | -89.47% | |
NET CHANGE | |||
Cash From Operating Activities | -4.300M | -5.000M | -5.100M |
Cash From Investing Activities | 6.800M | 5.800M | 11.00M |
Cash From Financing Activities | -5.000M | 0.000 | 200.0K |
Net Change In Cash | -2.464M | 800.0K | 6.100M |
YoY Change | -71.01% | -86.89% | -17.57% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$4.300M | -$5.000M | -$5.100M |
Capital Expenditures | $3.000K | -$200.0K | -$100.0K |
Free Cash Flow | -$4.303M | -$4.800M | -$5.000M |
YoY Change | -10.15% | -4.0% | -120.0% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2016Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
16071000 | |
CY2016Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
38090000 | |
CY2016Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
7000 | |
CY2016Q4 | us-gaap |
Liabilities
Liabilities
|
22019000 | |
CY2016Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-147982000 | |
CY2016Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
10264000 | |
CY2016Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
6800000 | |
CY2016Q4 | us-gaap |
Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
|
31000 | |
CY2015Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
66248000 | |
CY2015Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2015Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
CY2016Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2016Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
CY2015Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2015Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
762005 | |
CY2015Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
762005 | |
CY2015 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
326000 | |
CY2016Q4 | us-gaap |
Assets Current
AssetsCurrent
|
37521000 | |
CY2016Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
444000 | |
CY2016Q4 | us-gaap |
Assets
Assets
|
38090000 | |
CY2016Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
837000 | |
CY2016Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
596000 | |
CY2016Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
805000 | |
CY2015 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
272000 | |
CY2015 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-13802000 | |
CY2015 | us-gaap |
Operating Expenses
OperatingExpenses
|
15552000 | |
CY2016 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-20418000 | |
CY2016 | us-gaap |
Operating Expenses
OperatingExpenses
|
20817000 | |
CY2015Q4 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
33794000 | |
CY2015Q4 | us-gaap |
Deposits Assets Current
DepositsAssetsCurrent
|
133000 | |
CY2015Q4 | us-gaap |
Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
|
492000 | |
CY2015 | cbio |
Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
|
518000 | |
CY2016 | cbio |
Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
|
3473000 | |
CY2015 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-14762000 | |
CY2016 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
CY2016 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2016 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
CY2016 | dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | |
CY2017Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
1000036 | |
CY2016Q2 | dei |
Entity Public Float
EntityPublicFloat
|
12081112 | |
CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
29096000 | |
CY2015Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
3402000 | |
CY2016Q4 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
19468000 | |
CY2016Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
958000 | |
CY2015Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1781000 | |
CY2015Q4 | us-gaap |
Assets Current
AssetsCurrent
|
68698000 | |
CY2016Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
125000 | |
CY2015Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
125000 | |
CY2015Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
698000 | |
CY2015Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
66247000 | |
CY2015Q4 | us-gaap |
Assets
Assets
|
69521000 | |
CY2015Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
939000 | |
CY2015Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
926000 | |
CY2015Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
535000 | |
CY2016Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
283000 | |
CY2015Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
438000 | |
CY2016Q4 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
41000 | |
CY2015Q4 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
19000 | |
CY2016Q4 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
19403000 | |
CY2015Q4 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
33743000 | |
CY2015Q4 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
1156000 | |
CY2016Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
21965000 | |
CY2015Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
37756000 | |
CY2016Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
47000 | |
CY2015Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
292000 | |
CY2015Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
48000 | |
CY2015Q4 | us-gaap |
Liabilities
Liabilities
|
38096000 | |
CY2016Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
CY2015Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
CY2016Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
1000 | |
CY2015Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
1000 | |
CY2016Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
164053000 | |
CY2015Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
162460000 | |
CY2016Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-1000 | |
CY2015Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
1000 | |
CY2015Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-131037000 | |
CY2015Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
31425000 | |
CY2015Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
69521000 | |
CY2015Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2015Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
CY2016Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2016Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2016Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
CY2016Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
801756 | |
CY2016Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
801756 | |
CY2016 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
9262000 | |
CY2015 | us-gaap |
Interest Expense
InterestExpense
|
1478000 | |
CY2016 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16945000 | |
CY2016 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-21.75 | |
CY2015 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-49.99 | |
CY2016 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
779166 | |
CY2015 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
295272 | |
CY2016 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-2000 | |
CY2015 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
1000 | |
CY2015 | us-gaap |
Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
|
7259000 | |
CY2016 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-16947000 | |
CY2015 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-14761000 | |
CY2014Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-109352000 | |
CY2015 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
326000 | |
CY2015 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
13000 | |
CY2015 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
117647000 | |
CY2015 | us-gaap |
Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
|
774000 | |
CY2015 | us-gaap |
Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
|
36537000 | |
CY2016 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
635000 | |
CY2016 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
957000 | |
CY2016 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
635000 | |
CY2015 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
326000 | |
CY2016 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
389000 | |
CY2015 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
470000 | |
CY2015 | us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
1478000 | |
CY2016 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
557000 | |
CY2015 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-15000 | |
CY2016 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
1674000 | |
CY2016 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
99000 | |
CY2015 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
52000 | |
CY2015 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-91000 | |
CY2016 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
1057000 | |
CY2015 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
242000 | |
CY2016 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-461000 | |
CY2015 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
79000 | |
CY2016 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-956000 | |
CY2016 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-102000 | |
CY2016 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-60000 | |
CY2016 | us-gaap |
Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
|
19000 | |
CY2015 | us-gaap |
Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
|
-41000 | |
CY2016 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-400000 | |
CY2015 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-1749000 | |
CY2016 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-18472000 | |
CY2015 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-19118000 | |
CY2015 | cbio |
Proceeds From Reverse Merger
ProceedsFromReverseMerger
|
23931000 | |
CY2016 | us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
10002000 | |
CY2015 | us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
13823000 | |
CY2016 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
13401000 | |
CY2016 | us-gaap |
Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
|
1674000 | |
CY2016 | us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
5000 | |
CY2015 | us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
125000 | |
CY2016 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
890000 | |
CY2016 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
468000 | |
CY2016 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-1308000 | |
CY2015 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
37357000 | |
CY2016 | us-gaap |
Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
|
14330000 | |
CY2015 | us-gaap |
Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
|
3255000 | |
CY2016 | us-gaap |
Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
|
14340000 | |
CY2015 | us-gaap |
Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
|
3020000 | |
CY2016 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
958000 | |
CY2015 | us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
1888000 | |
CY2015 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
82000 | |
CY2015 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
13000 | |
CY2016 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
948000 | |
CY2015 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
9313000 | |
CY2016 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-18832000 | |
CY2015 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
27552000 | |
CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1544000 | |
CY2015 | cbio |
Investment Securities Received From Reverse Merger
InvestmentSecuritiesReceivedFromReverseMerger
|
17223000 | |
CY2015 | cbio |
Redeemable Convertible Notes Assumed Upon Reverse Merger
RedeemableConvertibleNotesAssumedUponReverseMerger
|
37073000 | |
CY2016 | cbio |
Noncash Or Part Noncash Unrealized Gain Loss On Investments
NoncashOrPartNoncashUnrealizedGainLossOnInvestments
|
-2000 | |
CY2015 | cbio |
Noncash Or Part Noncash Unrealized Gain Loss On Investments
NoncashOrPartNoncashUnrealizedGainLossOnInvestments
|
1000 | |
CY2015 | cbio |
Embedded Derivative Related To Redeemable Convertible Notes
EmbeddedDerivativeRelatedToRedeemableConvertibleNotes
|
1455000 | |
CY2016 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:5.24%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Nature of Operations</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc. (the “Company” or “Catalyst”), is a clinical-stage biotechnology company focused on developing novel medicines to address hematology indications, including the treatment of hemophilia. Its facilities are in South San Francisco, California and it operates in one segment.</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 10, 2017, the Company effected a reverse stock split of its common stock at a ratio of 1-for-15 (“2017 Reverse Stock Split”). The 2017 Reverse Stock Split was approved by the Company’s stockholders at a special meeting of stockholders held on February 2, 2017. As a result of the 2017 Reverse Stock Split, each 15 pre-split shares of common stock outstanding were automatically combined into one new share of common stock, and the number of outstanding shares of common stock on the date of the split was reduced from approximately 13.0 million shares to approximately 868,000 shares. Unless otherwise specified, all share and per share amounts in these notes and the accompanying consolidated financial statements are reported on a post-stock split basis for all periods presented.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reverse Merger</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to August 20, 2015, the name of the Company was Targacept, Inc. On August 20, 2015, Targacept completed its business combination with Catalyst Bio, Inc. (“Catalyst Bio”) in accordance with the terms of an Agreement and Plan of Merger, dated as of March 5, 2015, as amended on May 6 and May 13, 2015, by and among Targacept, Talos Merger Sub, Inc. (“Merger Sub”) and Catalyst Bio, pursuant to which Merger Sub merged with and into Catalyst Bio, with Catalyst Bio surviving as a wholly-owned subsidiary of Targacept (the “Merger”). Also on August 20, 2015, in connection with, and prior to the completion of, the Merger, Targacept effected a 1-for-7 reverse stock split of its common stock (the “Reverse Stock Split”) and changed its name from Targacept, Inc. to Catalyst Biosciences, Inc. Following the completion of the Merger, the business conducted by the Company became primarily the business conducted by Catalyst Bio described in the paragraph above. We refer in this Annual Report on Form 10-K to the business combination as the “Merger,” to the Company prior to the Merger as “Targacept” and to our subsidiary as “Catalyst Bio,” and discussions of historical results reflect the results of Catalyst Bio prior to the completion of the Merger and do not include the historical results of Targacept prior to the completion of the Merger. </p> <p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 19, 2015, prior to and in connection with the Merger, the Company paid a dividend to the Targacept holders consisting of cash and non-interest bearing redeemable convertible notes (the “Pre-Closing Dividend”), see <font style="font-style:italic;">Note 9</font> for further detail. In connection with the Pre-Closing Dividend and the reverse-stock split, the Company adjusted the number of shares subject to each outstanding option to purchase its common stock. On August 20, 2015, upon the completion of the Merger, the Company issued shares of its common stock to Catalyst Bio stockholders in exchange for each share of Catalyst Bio common stock outstanding immediately prior to the Merger and assumed all the outstanding options and warrants of Catalyst Bio, with such options and warrants henceforth representing the right to purchase a number of shares of the Company’s common stock. All preferred stock and warrants were converted to common stock and warrants to purchase common stock upon the closing of the Merger. </p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We had a net loss of $16.9 million for the year ended December 31, 2016 and an accumulated deficit of $148.0 million as of December 31, 2016 and expect to continue to incur losses for the next several years. As of December 31, 2016, we had $17.1 million in cash, cash equivalents and short-term investments, a $16.9 million net loss and $18.5 million cash used in operations. Management believes that the currently available resources, including cash, cash equivalents and short term investments as well as the cash raised from the sale of common stock in January 2017 (see Note 14) and availability under our Capital on Demand Sales Agreement (See Note 14), will provide sufficient funds to enable us to meet its operating plan for at least the next twelve months from the date of this filing. </p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">However, if our anticipated operating results are not achieved in future periods, management believes that planned expenditures can be reduced to extend the time period over which the then-available resources would be able to fund our operations. We plan to continue to fund losses from operations and capital funding needs through future equity and/or debt financings, as well as potential additional asset sales, licensing transactions, collaborations or strategic partnerships with other companies. The sale of additional equity or convertible debt could result in additional dilution to our stockholders. The incurrence of indebtedness would result in debt service obligations and could result in operating and financing covenants that would restrict our operations. We can provide no assurance that financing will be available in the amounts we need or on terms acceptable to us, if at all. If we are not able to secure adequate additional funding we may be forced to delay, make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially harm our business.</p></div> | |
CY2015 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
700000 | |
CY2016 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, convertible notes and related warrants up to the date of conversion, common stock and stock-based compensation. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p></div> | |
CY2016Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
|
1137000 | |
CY2015Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
|
1285000 | |
CY2016Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
745000 | |
CY2015 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
0 | |
CY2016 | cbio |
Operating Lease Expiration Date
OperatingLeaseExpirationDate
|
2018-02 | |
CY2016 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
700000 | |
CY2016Q4 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
17100000 | |
CY2016 | cbio |
Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
|
100000 | |
CY2015 | cbio |
Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
|
900000 | |
CY2015Q4 | us-gaap |
Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
|
1156000 | |
CY2015Q4 | us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
|
1156000 | |
CY2016 | us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
|
-1057000 | |
CY2016 | us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
|
-99000 | |
CY2016Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
36551000 | |
CY2016Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
2000 | |
CY2016Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
36549000 | |
CY2015Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
2000 | |
CY2015Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
1000 | |
CY2015Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
66248000 | |
CY2016 | us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
0 | |
CY2016Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
2304000 | |
CY2015Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
6399000 | |
CY2016Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1860000 | |
CY2015Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
5701000 | |
CY2016 | us-gaap |
Depreciation
Depreciation
|
400000 | |
CY2015 | us-gaap |
Depreciation
Depreciation
|
500000 | |
CY2016 | us-gaap |
Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
|
600000 | |
CY2015 | us-gaap |
Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
|
0 | |
CY2016Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
125000 | |
CY2016Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
870000 | |
CY2013 | cbio |
License Fees Payable
LicenseFeesPayable
|
100000 | |
CY2016 | us-gaap |
Interest Expense Related Party
InterestExpenseRelatedParty
|
0 | |
CY2015 | us-gaap |
Interest Expense Related Party
InterestExpenseRelatedParty
|
1500000 | |
CY2016 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
635000 | |
CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.3400 | |
CY2016Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
25944000 | |
CY2015Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
17650000 | |
CY2016Q4 | cbio |
Deferred Tax Assets Fixed Assets And Intangibles
DeferredTaxAssetsFixedAssetsAndIntangibles
|
114000 | |
CY2016 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P7Y1M2D | |
CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
15524910 | |
CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
16683 | |
CY2015 | cbio |
Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod
|
94721 | |
CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
45039 | |
CY2015 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
254 | |
CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
2436 | |
CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
7119 | |
CY2016 | cbio |
Aggregate Fractional Shares Written Off Upon Conversion Of Options Assumed In Merger
AggregateFractionalSharesWrittenOffUponConversionOfOptionsAssumedInMerger
|
4 | |
CY2016 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
6573 | |
CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
140990 | |
CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
106472 | |
CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
|
68977 | |
CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
85849 | |
CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
134.40 | |
CY2015 | cbio |
Sharebased Compensation Arrangements By Sharebased Payment Award Options Assumed In Merger Weighted Average Exercise Price
SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice
|
227.40 | |
CY2015 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
44.70 | |
CY2015 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
50.70 | |
CY2015 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
127.20 | |
CY2015 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
708.00 | |
CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
147.45 | |
CY2016 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
23.70 | |
CY2016 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
259.05 | |
CY2016 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
64.95 | |
CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
128.25 | |
CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
152.70 | |
CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
|
74.70 | |
CY2014 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P5Y6M4D | |
CY2015 | cbio |
Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Merger Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageRemainingContractualTerm
|
P4Y4D | |
CY2015 | cbio |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted
|
P9Y9M22D | |
CY2015 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P5Y6M4D | |
CY2016 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P3Y11M5D | |
CY2016 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P2Y3M11D | |
CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.0133 | |
CY2015 | cbio |
Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
|
-0.0800 | |
CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
|
-0.1159 | |
CY2015 | cbio |
Effective Income Tax Rate Reconciliation Derecognition
EffectiveIncomeTaxRateReconciliationDerecognition
|
-2.4087 | |
CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
2.0417 | |
CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
|
0.0043 | |
CY2016Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
3174000 | |
CY2015Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
2625000 | |
CY2015Q4 | cbio |
Deferred Tax Assets Fixed Assets And Intangibles
DeferredTaxAssetsFixedAssetsAndIntangibles
|
95000 | |
CY2016Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
30369000 | |
CY2015Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
21655000 | |
CY2016 | cbio |
Research And Development Tax Credit Carry Forwards Derecognized
ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized
|
5600000 | |
CY2016Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
1539000 | |
CY2015Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
1314000 | |
CY2014Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
2570000 | |
CY2015 | us-gaap |
Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
|
1347000 | |
CY2015 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
91000 | |
CY2016 | us-gaap |
Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
|
-6000 | |
CY2016 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
219000 | |
CY2016Q4 | us-gaap |
Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
|
0 | |
CY2015Q4 | us-gaap |
Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
|
0 | |
CY2016 | cbio |
Change In Derivative Liability
ChangeInDerivativeLiability
|
1156000 | |
CY2015 | cbio |
Change In Derivative Liability
ChangeInDerivativeLiability
|
387000 | |
CY2016 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
86000 | |
CY2015 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
131000 | |
CY2016 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
293796 | |
CY2015 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
403572 |